| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Naloxegel |
| Brand | Moventig® |
| Indication | Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). |
| Assessment Process | |
| Rapid review commissioned | 10/02/2015 |
| Rapid review completed | 13/04/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |
Naloxegel (Moventiq®) is to be reimbursed under the Community Drugs Schemes subject to conditions.